Shares of Artiva Biotherapeutics Inc. (ARTV) are down nearly 45% from their 52-week high of $14.53, recorded this April, and trade around $8.
This clinical-stage biotechnology company is developing a deep B-cell-depleting therapy for patients with refractory rheumatoid arthritis (RA) who have experienced inadequate response or treatment failure with two or more biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.